Adicet Bio, Inc.
ACET- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720580
No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Adicet Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Adicet Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Klickstein Lloyd | Chief Medical Officer | 108,566 | Aug 7, 2026 | 2 |
| Dubin Steve | Director | 22,700 | Jun 23, 2026 | 1 |
| Schor Chen | President & CEO | 6,820 | Jun 23, 2026 | 3 |
| Chodakewitz Jeffrey | Director | 17,700 | Jun 23, 2026 | 1 |
| Grissinger Michael | Director | – | Jun 23, 2026 | 1 |
| Sinclair Andrew | Director | 17,700 | Jun 23, 2026 | 1 |
| Aftab Blake | Chief Scientific Officer | 2,981 | Jun 23, 2026 | 3 |
| Peng Katie | Director | 11,800 | Jun 23, 2026 | 1 |
| RA Capital Healthcare Fund LP | 10% Owner | 932,624Indirect | Apr 29, 2026 | 2 |
| Ra Capital Management, L.P. | 10% Owner | 932,624Indirect | Apr 29, 2026 | 2 |
| Kolchinsky Peter | 10% Owner | 932,624Indirect | Apr 29, 2026 | 2 |
| Shah Rajeev M. | 10% Owner | 932,624Indirect | Apr 29, 2026 | 2 |
| OrbiMed Advisors LLC | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Israel GP Ltd. | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Israel BioFund GP Limited Partnership | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Capital GP V LLC | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Israel GP II, L.P. | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Advisors Israel II Ltd | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Capital GP VI LLC | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| OrbiMed Genesis GP LLC | 10% Owner | 0Indirect | Apr 9, 2026 | 2 |
| Harvey Brian Nicholas | Chief Financial Officer | 5,145 | Mar 27, 2026 | 2 |
| Healey Don | Chief Technology Officer | 3,452 | Mar 27, 2026 | 2 |
| Maltzman Julia D. | Chief Medical Officer | – | Mar 27, 2026 | 1 |
| Gordon Carl L | Director, 10% Owner | 11,800 | Aug 23, 2024 | 0 |
| Kauffman Michael | Director | 5,900 | Aug 23, 2024 | 0 |
| Jakobovits Aya | Director | 11,800 | Aug 23, 2024 | 0 |
| Galimi Francesco | SVP & Chief Medical Officer | 101,801 | Jun 7, 2024 | 0 |
| Sanna Bastiano | Director | 5,900 | Aug 16, 2023 | 0 |
| Chimovits Erez | Director, 10% Owner | 748,054Indirect | Jun 29, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 (view filing) | Dec 8 | 5 days | Sinclair AndrewDirector | PPurchase | +500.0K | $14.00 | +$7.00M | +31.0%2.12M after | Amended |
| Feb 14, 2022 (view filing) | Jan 3-Feb 9 | 42 daysLate | Jakobovits AyaDirector | SSale | −24.0K | $16.51 | −$396.1K | −6.2%360.3K after | 6 lots |
| Feb 17, 2022 (view filing) | Feb 16 | 1 day | Jakobovits AyaDirector | SSale | −4.00K | $14.83 | −$59.3K | −1.1%358.3K after | 2 lots |
| Mar 11, 2022 (view filing) | Mar 9 | 2 days | Jakobovits AyaDirector | SSale | −4.00K | $14.00 | −$56.0K | −1.1%356.3K after | 2 lots |
| Apr 5, 2022 (view filing) | Apr 1-4 | 4 days | Galimi FrancescoSVP & Chief Medical Officer | SSale | −15.6K | $21.00 | −$327.6K | −20.7%59.9K after | 4 lots |
| Jul 7, 2022 (view filing) | Jul 5 | 2 days | Aftab BlakeChief Scientific Officer | SSale | −1.36K | $14.50 | −$19.8K | −2.5%52.9K after | |
| Aug 3, 2022 (view filing) | Aug 1 | 2 days | Aftab BlakeChief Scientific Officer | SSale | −6.97K | $16.64 | −$115.9K | −13.2%45.9K after | |
| Aug 5, 2022 (view filing) | Aug 3 | 2 days | Aftab BlakeChief Scientific Officer | SSale | −6.97K | $18.00 | −$125.4K | −15.2%39.0K after | |
| Sep 13, 2022 (view filing)4:59 PM ET | Sep 9-13 | 4 days | Schor ChenPresident & CEO | SSale | −78.4K | $16.80 | −$1.32M | −36.0%139.7K after | 4 lots |
| Sep 16, 2022 (view filing) | Sep 14 | 2 days | Schor ChenPresident & CEO | SSale | −952 | $18.00 | −$17.1K | −0.7%138.7K after | |
| Oct 14, 2022 (view filing) | Oct 12 | 2 days | Aftab BlakeChief Scientific Officer | SSale | −1.65K | $15.40 | −$25.3K | −3.1%51.2K after | |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Aftab BlakeChief Scientific Officer | SSale | −8.07K | $16.27 | −$131.3K | −18.7%35.2K after | |
| Nov 4, 2022 (view filing) | Nov 2-3 | 2 days | Schor ChenPresident & CEO | SSale | −25.3K | $18.04 | −$456.6K | −18.2%113.4K after | 2 lots |
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Schor ChenPresident & CEO | SSale | −30.0K | $19.05 | −$571.5K | −26.4%83.4K after | |
| Nov 15, 2022 (view filing) | Nov 10 | 5 days | Schor ChenPresident & CEO | SSale | −9.96K | $21.03 | −$209.4K | −9.8%91.5K after | |
| Nov 15, 2022 (view filing) | Nov 10 | 5 days | Schor ChenPresident & CEO | SSale | −30.0K | $20.06 | −$601.8K | −36.0%53.4K after | |
| Nov 15, 2022 (view filing) | Nov 10 | 5 days | Aftab BlakeChief Scientific Officer | SSale | −6.97K | $21.00 | −$146.3K | −19.8%28.2K after | |
| Feb 14, 2023 (view filing) | Feb 10 | 4 days | Healey DonChief Technology Officer | SSale | −10.5K | $7.98 | −$83.5K | −12.8%71.1K after | |
| Feb 17, 2023 (view filing) | Feb 15 | 2 days | Healey DonChief Technology Officer | SSale | −4.53K | $7.57 | −$34.3K | −6.4%66.6K after | |
| Jun 29, 2023 (view filing) | Jun 27 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +875.0K | $2.09 | +$1.83M | New position748.1K after | 4 lots |
| Jun 29, 2023 (view filing)4:46 PM ET | Jun 27 | 2 days | OrbiMed Advisors LLC and 8 othersDirector, 10% Owner | PPurchase | +875.0K | $2.09 | +$1.83M | New position748.1K after | 4 lotsDuplicate filing |
| Jun 30, 2023 (view filing) | Jun 30 | Same day | Dubin SteveDirector | PPurchase | +5.00K | $2.40 | +$12.0K | +84.7%10.9K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Schor ChenPresident & CEO | SSale | −5.50K | $1.42 | −$7.81K | −12.7%38.0K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Schor ChenPresident & CEO | PPurchase | +5.50K | $1.42 | +$7.81K | +3.1%182.5K after | |
| Oct 2, 2023 (view filing) | Sep 29 | 3 days | Schor ChenPresident & CEO | SSale | −5.50K | $1.36 | −$7.48K | −3.0%177.0K after | |
| Oct 2, 2023 (view filing) | Oct 2 | Same day | Schor ChenPresident & CEO | PPurchase | +5.50K | $1.33 | +$7.32K | +14.5%43.5K after | |
| Jan 26, 2024 (view filing) | Jan 25 | 1 day | Gordon Carl LDirector, 10% Owner | PPurchase | +3.13M | $2.40 | +$7.50M | New position1.26M after | 3 lots |
| Jan 26, 2024 (view filing)7:14 PM ET | Jan 25 | 1 day | OrbiMed Advisors LLC and 7 othersDirector, 10% Owner | PPurchase | +3.13M | $2.40 | +$7.50M | New position1.26M after | 3 lotsDuplicate filing |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Kauffman MichaelDirector | SSale | −5.90K | $1.43 | −$8.44K | −50.0%5.90K after | |
| Oct 10, 2025 (view filing)8:06 PM ET | Oct 8 | 2 days | OrbiMed Advisors LLC and 7 others10% Owner | PPurchase | +5.00M | $1.00 | +$5.00M | New position4.49M after | 2 lots |
| Apr 9, 2026 (view filing)5:38 PM ET | Apr 7-8 | 2 days | OrbiMed Advisors LLC and 7 others10% Owner | SSale | −104.7K | $6.45 | −$674.8K | −100.0%0 after | 4 lots |
| Apr 13, 2026 (view filing)5:20 PM ET | Feb 18-20 | 54 daysLate | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +223.6K | $7.17 | +$1.60M | +23.3%1.18M after | 3 lots |